Antimicrobial update.
New and soon-to-be introduced antimicrobials are reviewed and compared with agents already in use to determine possible therapeutic and/or cost advantages. Drugs discussed are amdinocillin, ticarcillin/clavulanic acid, ceftriaxone, ceftazidime, imipenem/cilastatin, aztreonam, and quinolones.
D000560:Amdinocillin / Q000378:metabolism / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D001398:Aztreonam / Q000378:metabolism / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects; D002442:Ceftazidime / Q000378:metabolism / Q000627:therapeutic use; D002443:Ceftriaxone / Q000378:metabolism / Q000627:therapeutic use; D015377:Cilastatin; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000378:metabolism / Q000627:therapeutic use; D003521:Cyclopropanes / Q000627:therapeutic use; D004150:Dipeptidases / Q000037:antagonists & inhibitors; D006801:Humans; D015378:Imipenem; D013845:Thienamycins / Q000627:therapeutic use; D013982:Ticarcillin / Q000378:metabolism / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D003521:Cyclopropanes; D013845:Thienamycins; D015377:Cilastatin; D019818:Clavulanic Acid; D015378:Imipenem; D002443:Ceftriaxone; D002442:Ceftazidime; D004150:Dipeptidases; D013982:Ticarcillin; D001398:Aztreonam; D000560:Amdinocillin